Actively Recruiting
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
Led by Mayo Clinic · Updated on 2026-02-06
45
Participants Needed
2
Research Sites
444 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease
CONDITIONS
Official Title
Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63; 18 years
- Histological confirmation of primary breast cancer
- Metastatic breast cancer with at least 12 months of response to first-line systemic therapy followed by 1-3 extracranial oligoprogressive sites, planning to continue current systemic therapy
- Metastatic breast cancer with at least 6 months of response to second-line or later systemic therapy, with 1-3 extracranial oligoprogressive sites
- ECOG Performance Status 64; 2
- Negative urine or serum pregnancy test 64; 7 days prior to registration for women of childbearing potential
- Ability to complete questionnaires independently or with help
- Provide written informed consent
- Willingness to return for follow-up during the Active Monitoring Phase
- Willing to provide blood samples for research
- Receiving radiation therapy as specified in the protocol
You will not qualify if you...
- Male patients
- Nursing or pregnant women
- Men or women of childbearing potential unwilling to use adequate contraception
- Patients with triple negative breast cancer (negative for ER, PR, and HER2)
- Active second primary cancer
- More than 3 extracranial sites of oligoprogressive disease
- Active central nervous system disease, except stable and treated asymptomatic CNS lesions without recent corticosteroids
- Active connective tissue disease posing excessive risk of toxicity
- Prior radiation overlapping intended treatment area deemed unsafe by Radiation Oncologist
- Note: Some prior radiation overlap considered safe by Radiation Oncologist allowed
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259
Actively Recruiting
2
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Actively Recruiting
Research Team
C
Clinical Trials Referral Office
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here